1.Ghaffari S, Torabi-Rahvar M, Aghayan S, Jabbarpour Z, Moradzadeh K, Omidkhoda A,  Ahmadbeigi N. Optimizing interleukin-2 concentration, seeding density and bead-to-cell ratio of T-cell expansion for adoptive immunotherapy. BMC Immunol 22, 43 (2021).

 

2.Anajafi S, Ranjbar A, Torabi-Rahvar M, Ahmadbeigi N. In vivo study of the angiogenesis potential of bone marrow-derived mesenchymal stem cell aggregates in their niche like environment. Int J Artif Organs. 2021 Oct;44(10):727-733. doi: 10.1177/03913988211025538. Epub 2021 Jul 10. PMID: 34250831.

 

3.Monzavi SM, Naderi M, Ahmadbeigi N, Kajbafzadeh AM, Muhammadnejad S. An outlook on antigen-specific adoptive immunotherapy for viral infections with a focus on COVID-19. Cell Immunol. 2021;367:104398. doi:10.1016/j.cellimm.2021.104398.

 

4.Ahmadbeigi N, Alatab S, Vasei M, Ranjbar A, Aghayan S, khorsand A, Moradzadeh K, Darvishyan Z, Jamali M, Muhammadnejad S. Characterization of a xenograft model for anti-CD19 CAR T cell studies. Clin Transl Oncol (2021).

5.Ghojoghi R, Nekooei F, Vatanparast F, et al. The role of coagulation factors VII, VIII, and IX on the tropism and inflammatory effect of Adenovector on liver and breast cell lines. Research Square; 2021. DOI: 10.21203/rs.3.rs-458048/v1.

 

6.Torabi-Rahvar M, Aghayan HR, Ahmadbeigi N. Antigen-independent killer cells prepared for adoptive immunotherapy: One source, divergent protocols, diverse nomenclature. J Immunol Methods. 2020 Feb;477:112690. doi: 10.1016/j.jim.2019.112690. Epub 2019 Nov 1. PMID: 31678265.

 

7.Jabbarpour Z, Kiani J, Keshtkar S, Saidijam M, Ghahremani MH, Ahmadbeigi N. Effects of human placenta-derived mesenchymal stem cells with NK4 gene expression on glioblastoma multiforme cell lines. J Cell Biochem. 2020 Feb;121(2):1362-1373. doi: 10.1002/jcb.29371. Epub 2019 Oct 8. PMID: 31595570.

 

8.Jabbarpour Z, Ghahremani MH, Saidijam M, Kiani J, Ahmadbeigi N. Trends of Stem Cell-Based Clinical Trials in Gastrointestinal Tract Diseases. Journal of Analytical Oncology. 2020;9(1):56-62.

 

9.Ghaffari S, Torabi‐Rahvar M, Omidkhoda A, Ahmadbeigi N. Impact of various culture conditions on ex vivo expansion of polyclonal T cells for adoptive immunotherapy. Apmis. 2019 Dec;127(12):737-45.

 

10.Sotoudeh M, Shakeri R, Dawsey SM, Sharififard B, Ahmadbeigi N, Naderi M. ANTXR1 (TEM8) overexpression in gastric adenocarcinoma makes the protein a potential target of immunotherapy. Cancer Immunology, Immunotherapy. 2019 Oct;68(10):1597-603.

 

11.Alatab S, Shekarchian S, Njafi I, Moghadasali R, Pourmand MR, Ahmadbeigi N, Bolurieh T, Jaroughi N, Pourmand* G, Aghdami N. PD09-05 SYSTEMIC INFUSION OF AUTOLOGOUS ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS IN PERITONEAL DIALYSIS PATIENTS: FEASIBILITY AND SAFETY. The Journal of Urology. 2019 Apr;201(Supplement 4):e155-.

 

12.Sotoudeh M, Shirvani SI, Merat S, Ahmadbeigi N, Naderi M. MSLN (Mesothelin), ANTXR1 (TEM8), and MUC3A are the potent antigenic targets for CAR T cell therapy of gastric adenocarcinoma. Journal of cellular biochemistry. 2019 Apr;120(4):5010-7.

 

13.Alatab S, Najafi I, Tabatabaei-Malazy O, Pourmand G, Ahmadbeigi N. Strategies for prevention and treatment of peritoneal fibrosis: a scientometric study. International journal of preventive medicine. 2019;10.

 

14.Kiani J, Naderi M, Torabi-Rahvar M, Ranjbar A, Aghayan HR, Janzamin E, Ahmadbeigi N. Generation of CD19-targeted chimeric antigen receptor T cells. Archives of Iranian medicine. 2019 Jan 1;22(1):7-10.

 

15.Soltani SK, Forogh B, Ahmadbeigi N, Kharazi HH, Fallahzadeh K, Kashani L, Karami M, Kheyrollah Y, Vasei M. Safety and efficacy of allogenic placental mesenchymal stem cells for treating knee osteoarthritis: a pilot study. Cytotherapy. 2019 Jan 1;21(1):54-63.

 

16.Alatab S, Shekarchian S, Najafi I, Moghadasali R, Ahmadbeigi N, Pourmand MR, Bolurieh T, Jaroughi N, Pourmand G, Aghdami N. Systemic infusion of autologous adipose tissue-derived mesenchymal stem cells in peritoneal dialysis patients: feasibility and safety. Cell Journal (Yakhteh). 2019;20(4):483.

 

17.Kamalabadi-Farahani M, Vasei M, Ahmadbeigi N, Ebrahimi-Barough S, Soleimani M, Roozafzoon R. Anti-tumour effects of TRAIL-expressing human placental derived mesenchymal stem cells with curcumin-loaded chitosan nanoparticles in a mice model of triple negative breast cancer. Artificial cells, nanomedicine, and biotechnology. 2018 Nov 12;46(sup3):S1011-21.

 

18.Khatami F, Torabi-Rahvar M, Kiani J, Naderi M, Ahmadbeigi N. Addressing cancer immunotherapy research in Iran: adoptive cell therapy on the horizon. Cytotherapy. 2018 Oct 1;20(10):1227-37.

 

19.Arabi F, Torabi-Rahvar M, Shariati A, Ahmadbeigi N, Naderi M. Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials. Experimental cell research. 2018 Aug 1;369(1):1-0.

 

20.Babaei A, Katoonizadeh A, Ranjbar A, Naderi M, Ahmadbeigi N. Directly injected native bone-marrow stem cells cannot incorporate into acetaminophen-induced liver injury. Biologicals. 2018 Mar 1;52:55-8.

 

21.Omid H, Paryab A, Nakhli Y, Moradzadeh K, Madaah Hosseini HR, Sajadi N, Ahmadbeigi N. The effect of SPIO nanoparticles size on transduction of PEGylated lentiviral vector (submitted to Materials Today Nano)

 

22.Jabbarpour Z, Aghayan S, Moradzadeh K, Ghaffari S, Torabi-Rahvar M, Ahmadbeigi N. Identification of the effect of serum origin on cytokines induced killer cells expansion. (submitted to Journal of Translational Medicine)

 

23.Muhammadnejad S, Monzavi SM, Torabi-Rahvar M, Sotoudeh M, Muhammadnejad A, S, Ranjbar A, Aghayan S, Khorsand AA, Moradzadeh K, Janzamin E, Ahmadbeigi N. Effects of Adoptively Transferred Allogeneic CIK Cells on Colorectal Cancer: A Preclinical Study (submitted)

 

اشتراک گذاری در شبکه های اجتماعی